The Only Monthly Membership With a Positive ROI!

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Regeneron Pharmaceuticals

REGNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$1199.12

11.460.96%

At Close: -

$1199.12

00.00%

After Hours: 4:37 PM EDT

15 minutes delayed

Regeneron Pharmaceuticals (REGN) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals Stock (NASDAQ: REGN)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, August 23, 2024

What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Benzinga Insights
Piper Sandler Maintains Overweight on Regener...
Benzinga Newsdesk

Wednesday, August 21, 2024

Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Benzinga Neuro

Tuesday, August 20, 2024

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Benzinga Insights

Tuesday, August 13, 2024

Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Benzinga Insights

Thursday, August 08, 2024

$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Benzinga Insights

Friday, August 02, 2024

JP Morgan Maintains Overweight on Regeneron P...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Regeneron...
Benzinga Newsdesk
Guggenheim Maintains Buy on Regeneron Pharmac...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Regeneron...
Benzinga Newsdesk
Barclays Maintains Overweight on Regeneron Ph...
Benzinga Newsdesk
Analyst Ratings For Regeneron Pharmaceuticals
Benzinga Insights
Truist Securities Reiterates Buy on Regeneron...
Benzinga Newsdesk

Thursday, August 01, 2024

Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
Zacks
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Vandana Singh
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Piero Cingari
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Shanthi Rexaline
Regeneron Pharmaceuticals Q2 2024 Adj EPS $11...
Benzinga Newsdesk

Wednesday, July 31, 2024

Should You Invest in the iShares Biotechnology ETF?
Zacks

Tuesday, July 30, 2024

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Benzinga Insights

Monday, July 29, 2024

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Shanthi Rexaline

Thursday, July 25, 2024

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Vandana Singh

Tuesday, July 23, 2024

TD Cowen Maintains Buy on Regeneron Pharmaceu...
Benzinga Newsdesk
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Vandana Singh

Monday, July 22, 2024

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Benzinga Insights
Cantor Fitzgerald Maintains Neutral on Regene...
Benzinga Newsdesk

Friday, July 19, 2024

Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Benzinga Insights
Piper Sandler Maintains Overweight on Regener...
Benzinga Newsdesk

Thursday, July 18, 2024

Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Vandana Singh
Guggenheim Maintains Buy on Regeneron Pharmac...
Benzinga Newsdesk

Tuesday, July 16, 2024

Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Benzinga Insights

Monday, July 15, 2024

Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
Avi Kapoor

Thursday, July 11, 2024

The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
Benzinga Insights
Morgan Stanley Maintains Overweight on Regene...
Benzinga Newsdesk

Wednesday, July 10, 2024

Barclays Maintains Overweight on Regeneron Ph...
Benzinga Newsdesk

Monday, July 08, 2024

Regeneron Pharmaceuticals Expects Its Q2 GAAP...
Benzinga Newsdesk

Thursday, July 04, 2024

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Benzinga Insights

Wednesday, July 03, 2024

Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Vandana Singh
Regeneron and Sanofi's Dupixent Gains Europea...
Benzinga Newsdesk

Tuesday, July 02, 2024

Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Benzinga Insights
Shares of pharmaceutical stocks are trading l...
Benzinga Newsdesk

Friday, June 28, 2024

What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Vandana Singh
Regeneron's Odronextamab Receives Opinion fro...
Benzinga Newsdesk

Thursday, June 27, 2024

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
Vandana Singh
Canaccord Genuity Maintains Buy on Regeneron ...
Benzinga Newsdesk

Wednesday, June 26, 2024

Regeneron, Sanofi Present Phase 3 Trial For D...
Benzinga Newsdesk

Tuesday, June 25, 2024

Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Benzinga Insights
Argus Research Maintains Buy on Regeneron Pha...
Benzinga Newsdesk

Monday, June 24, 2024

Regeneron Pharmaceuticals' Approach To Improve Quality Of Weight Loss Has Merit: Goldman Sachs
Vandana Singh
The Analyst Verdict: Regeneron Pharmaceuticals In The Eyes Of 13 Experts
Benzinga Insights

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved